Good to see the are still looking at pbt2 for further development.
Also for pbt434:
Benign safety profile in GLP toxicology studies
• Non‐toxic dose exceeds efficacious dose by >10‐fold based on
allometric scaling
Ann: Investor presentation - Biotech Showcase, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
-0.001(10.0%) |
Mkt cap ! $82.14M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.0¢ | 0.9¢ | $48.56K | 4.989M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 44 | 17160918 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |